Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Heart Failure with a Preserved Ejection Fraction (HFpEF) | Subjects with diagnosed Heart failure with a preserved ejection fraction (HFpEF), non-obstructive Coronary Artery Disease (CAD), and have documented CMD. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cardiovascular Magnetic Resonance (CMR) | Diagnostic Test | Patients will consent to undergo a 50-minute non-invasive stress perfusion CMR. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in endocardial:epicardial perfusion ratio | Endocardial:Epicardial Perfusion Ratio is a measure of myocardial blood flow and will be determined by Cardiovascular magnetic resonance (CMR) | Baseline, 6 Months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Subjects included in the main CS-reducer HFPEF study (IRB# 25-002292)
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Diana Albers | Contact | 507-255-6884 | albers.diana2@mayo.edu |
| Name | Affiliation | Role |
|---|---|---|
| Claire Raphael, M.B.B.S., Ph.D. | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic | Recruiting | Rochester | Minnesota | 55905 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided